PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas

Inclusion Criteria:

• 1 At the age of 18~75, regardless the gender

• 2 The lesion of primary surgery was diagnosed as WHO II~IV Glioma by histologicpathology

• 3 Received radiotherapy and Temozolomide-based chemotherapy within 5 years

• 4 Recurrent and respectable gliomas, and have been neurosurgically resected

• 5 The resected recurrent gliomas was identified as WHO III~IV Glioma by histologicpathology

• 6 None postoperative standard therapeutic regimens can be followed whenparticipating the recruitment

• 7 Can understand the trial's content and sign informed consent

Exclusion Criteria:

• 1 Having other untreated malignant tumors

• 2 The amount of resected tumors is not enough for genomic sequencing or PTCs drugscreening

• 3 Received Carmustine implants within 6 months prior to enrollment

• 4 Subjects with active HBC, HCV or HIV infection

• 5 Subjects with uncontrolled cardio- or cerebro- vascular diseases

• 6 Subjects with uncontrolled psychiatric diseases or condition that could increaseadverse events or interfere the evaluation of outcomes

• 7 Subjects with other conditions in their active phase that would interfere trialparticipation

• 8 Subjects receiving immunosuppressants after organ transplantation

• 9 Subjects with unstable pulmonary embolism, deep venous embolism, or other majorarterial and venous thromboembolic events that occur within 30 days before theenrollment, or receiving anticoagulant therapy

• 10 Subjects in pregnancy or breastfeeding, or those who plan to become pregnantduring treatment or within 2 months after the end of treatment

• 11 Subjects with other conditions that would interfere participating in the trial atthe investigator's discretion

• 12 Subjects with medical conditions that affect signing the written informed consentor complying with the research procedures; or patients who are unwilling or unableto comply with the research procedures